A randomized, active-controlled clinical trial of fluocinolone acetonide 0.19 mg intravitreal implant for diabetic macular edema: Reductions in injection treatment burden – results from the NEW DAY study
Purpose: NEW DAY was a prospective, randomized, active-controlled, multicenter, phase 4, 18-month study (ClinicalTrials.gov ID NCT04469595). The study assessed the efficacy and safety of the fluocinolone acetonide (FAc; 0.19 mg) intravitreal implant as a baseline therapy in patients with center-involving [for full text, please go to the a.m. URL]
Authors
- Christopher D. Riemann (ORCID: https://orcid.org/0000-0003-2022-0951)
- Kamel Alkhatib
- Victor H. Gonzalez
- Michael Singer
- Mary Pao
- Charles C. Wykoff
- Christina Y. Weng
Institutions
- Baylor College of Medicine (US)
- Medical Center Ophthalmology Associates (US)
- Retina Consultants of Texas (US)
- ANI Pharmaceuticals (United States) (US)
- Cincinnati Eye Institute (US)
- West Texas Retina Consultants (US)
- Valley Retina Institute (US)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2026-06-17
- DOI
- https://doi.org/10.3205/26doc133
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00